Xofigo Clinical Trials

What Are Xofigo Clinical Trials?

Xofigo is a form of radiation therapy, delivered intravenously, to treat prostate cancer. It is a radioactive drug that is injected into the body, goes to the bones and helps kill cancer cells. Xofigo clinical trials are still being conducted to ensure the safety and efficacy of the drug in treating prostate cancer.

Xofigo clinical trials are necessary research studies that investigate the performance, safety, and effectiveness of this novel treatment in humans. Such studies are crucial for doctors and researchers in the development of new, and improvement of previous, forms of cancer treatments.

Why Is Xofigo Being Studied in Clinical Trials?

Prostate cancer cells depend on testosterone to grow and spread. The standard treatment paradigm for this type of cancer is hormone therapy that lowers overall testosterone levels in the body. Castration-resistant prostate cancer occurs when the prostate cancer continues to grow, even when testosterone levels have been significantly reduced.

The Food and Drug Administration (FDA) has approved the use of Xofigo to treat castration-resistant prostate cancer. However, the FDA has mainly allowed this use in clinical trials. Clinical trials are currently being performed to investigate the side effects and long term effects of Xofigo.

Xofigo is being studied because it may help men with prostate cancer that has spread to the bones. The drug may help relieve pain and other symptoms caused by cancer in the bones. It has also been beneficial in treating different types of cancer, such as breast cancer.

With further testing in clinical trials, doctors hope to learn more about the side effects of Xofigo and how well it works in treating prostate cancer. The FDA may approve Xofigo as a new breast and prostate cancer treatment if future tests go well.

How Does Xofigo Work?

Xofigo is a type of radiation therapy that is injected into a vein and travels through the bloodstream to the bones. It uses drugs that contain radioactive atoms, which release radiation as they decay. Once it reaches the bones, it gives off radiation to kill cancerous cells or stop them from growing. The radiation does not stay in the body for very long and will eventually leave the body through urine.

What Are Some of The Breakthrough Clinical Trials Involving Xofigo?

Some of the breakthrough trials for Xofigo include:

2021: This study showed prolonged survival in patients with metastatic castration-resistant prostate cancer. Given that this type of cancer is fatal, this was a significant breakthrough.

2019: A study published in the New England Journal of Medicine showed that men with metastatic hormone-sensitive prostate cancer who received Xofigo and androgen deprivation therapy (ADT) had a longer life expectancy with no disease progression compared to men who received ADT alone.

Other ongoing clinical trials test different ways to use Xofigo, such as combining it with other treatments.

Who Are The Key Opinion Leaders On Xofigo Clinical Trial Research?

Dr. Gabriel Hortobagyi, MD, from the University of Texas MD Anderson Cancer Center. His research focuses on Xofigo clinical trials and their efficacy in patients with metastatic breast cancer.

Dr. Howard Scher, MD, from Memorial Sloan-Kettering Cancer Center. His research focuses on Xofigo clinical trials and their efficacy in patients with metastatic prostate cancer.

Dr. Scott Kopetz, MD, from the University of Texas MD Anderson Cancer Center. He is the principal investigator of a Xofigo clinical trial where he investigates its performance in treating metastatic colorectal cancer.